GI Oncology Now’s Post

Insulin resistance is implicated in both the pathogenesis of #MASLD and its progression from steatosis to steatohepatitis #MASH, cirrhosis, and even hepatocellular carcinoma. https://lnkd.in/e8pNpVXF

Can ⁶⁸Ga-FAPI serve as a predictive biomarker for unresectable hepatocellular carcinoma? https://ow.ly/KVc750PrNgp #NuclearMedicine #PETscan #HeptocellularCarcinoma

Going to #ESMO23? We will be there from Oct 20-23. Come to booth 726a and explore the past, present, and potential future treatment options for unresectable hepatocellular carcinoma (uHCC). Plus, you can make an appointment to discuss the latest data. See you soon! https://hubs.ly/Q024bqv90 #ElevatingOutcomes #EveryMeasureMatters #ElevarAtESMO23

Get the latest perspectives on treatment approaches for unresectable advanced hepatocellular carcinoma. See all regions and reports available and download the sample report: https://lnkd.in/e9VA_Tvm #CancerResearch #GIcancer

Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C

#ESMO2023- #bladdercancer #urothelialcarcinoma highlights: EV302, CHECKMATE901, THOR, DAD- #DrBradleyMcGregor & I discuss practical implications of the data in advanced disease GU Oncology Now Bladder Cancer Advocacy Network -1) EV+pembro has a practice-changing impact in both cisplatin-eligible and ineligible patients as first-line therapy (median OS 31.5 mo, CR rate 29.1%), 2) Gemcitabine-Cisplatin-Nivolumab should be considered for cisplatin-eligible patients as first-line therapy (CR 22%, Median duration of CR 37 months, finite duration of chemo confers quality of life and cost benefits), 3) Erdafitinib superior to salvage chemo (relevant in clinic) but not superior to salvage pembrolizumab despite numerically better PFS and ORR (less relevant in clinic since PD1/L1 inhibitors have moved to 1st-line space), 4) combination of 2 ADCs, Enfortumab Vedotin and Sacituzumab govitecan promising for further development (non-overlapping targets, payloads and toxicities), 5) Impact of peri-op PD1 inhibition of first-line PD1 inhibitor based combinations and avelumab maintenance needs to be studied

🧪 A new study has demonstrated the potential of serum fusion transcripts in the screening and diagnostic process of hepatocellular carcinoma. ⚙️ Learn how a machine leaning model based on fusion transcript panels can monitor the impact of HCC treatment:

🩻 Discover our infographic that explains and details the read criteria modified RECIST for Hepatocellular Carcinoma (HCC): https://hubs.li/Q026pWDD0 #medicalimaging #HCC #mRECIST

Check out this exciting discussion on the reported drivers of T cell exhaustion in hepatocellular carcinoma and potential strategies to reverse it: https://lnkd.in/dsacSFgb  #Tcell #carcinoma #PharmacolRes #openaccess #Research #PharmaTwitter #MedTwitter  

Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma https://lnkd.in/dwFu2qgx